A new path to shorter drain duration?—a quick look at inactivated Pseudomonas preparation in nipple-sparing mastectomy with immediate prosthetic reconstruction Authors: Juan C. Torres, Robert K. Sigal, Oscar J. Manrique Published: 2026 Breast cancer remains one of the most common oncologic diseases today (1). From diagnosis through the course and outcome of treatment, breast cancer carries significant implications for both patients and physicians, as it can have devastating consequences not only affecting self-perception, but also intersecting with sexuality and motherhood, altering one of woman’s most visible physical characteristics (2,3). Among advances aimed at improving patients’ quality of life, nipple-sparing mastectomy with immediate prosthetic reconstruction (NSM-IPR) has demonstrated high patient satisfaction, improvement in quality of life, with favorable aesthetic outcomes. Up to now, various strategies have been studied to further improve these results (2,4). Despite these advances, associated complications remain frequent. Among them, postoperative infection continues to be a challenge. Drains in breast reconstruction have been identified as a potential source of infection, related to duration, location, and technique; drain duration in particular has been linked to the development of associated complications (5,6), and NSM-IPR is no exception (7). Zhao et al. recently published a single-center, prospective randomized controlled trial of 100 patients undergoing NSM-IPR, who were randomly assigned to receive an inactivated Pseudomonas aeruginosa preparation (PAP), a biologic agent thought to activate macrophages and promote a local immune response that aids wound healing and shortens drain duration (8), at varying concentrations. All procedures were performed by a single surgeon at Liaoning Cancer Hospital between January 2024 and January 2026. Inclusion criteria were patients with no distant metastasis, primary invasive breast cancer diagnosis, no prior breast surgery, and no pregnancy-associated breast cancer. Of the initial cohort, 75 patients were assigned to the PAP group and later were divided into three subgroups, sorted by concentration into low, medium, and high. In addition, 25 were assigned to a control group without PAP. The primary endpoint was drain duration; secondary endpoints included total drainage volume, postoperative complications, and cosmetic outcomes, assessed using the validated breast symmetry index (BSI) score and BREAST-Q instrument (7). Among the reported findings, drain removal time was significantly shorter in the PAP groups compared with control: mean duration was (13.4±1.98 days) in the low-concentration group, (10.76±2.17 days) in the medium-concentration group, and 10.76±1.88 days in the high-concentration group, vs. (15.92±2.58 days) in the control group (all P<0.001); on pairwise comparison, there was no significant difference between the medium- and high-concentration groups (P>0.99). Total drainage volume was also significantly lower in the PAP groups compared with control (P<0.001) and differed among concentrations, with the high concentration group averaging (444.8±34.26 mL) and showing a significant difference vs. the medium concentration PAP group, within subgroups. Regarding complications, eight cases of fever were reported, none of them exceeding 39 ℃ and all resolving within the first 24 hours with antipyretic treatment; five of these events occurred in the high concentration group, and the remaining three occurred one each in the other groups. Infection occurred only in the control and low-concentration groups with two events. Seroma occurred in three cases: two in the control group and one in the low-concentration group. The authors were also evaluating cosmetic outcomes, with two validated scales. BSI score showed no significant difference between the low-concentration and control groups (88.64±2.69 vs. 84.52±5.97, P=0.19), while the medium- and high-concentration groups scored significantly higher than control (93.48±1.29 and 95.52±1.05, respectively); with the high-concentration group showing the greatest difference and compared to medium concentration, significantly higher. On the BREAST-Q, satisfaction with breasts was higher in the low, medium, and high-concentration groups (75.92±6.06, 78.84±5.60, and 80.08±6.46, respectively) compared with control (59.84±7.07; all P<0.001), as was physical well-being (chest) (74.92±5.11, 77.80±5.05, and 78.56±5.67, respectively, vs. control 62.04±7.06; all P<0.001), with no significant differences among the PAP subgroups themselves. Finally, Zhao et al. propose that, building on the standard antimicrobial practice of povidone-iodine use, the addition of PAP may provide additional clinical benefit. They highlight that, among the PAP groups, drain indwelling time and total postoperative drainage volume were reduced, and that the medium-concentration group may represent the optimal choice, as it achieved similar results to the high concentration group without the associated increase in complications (6,7). The authors note considered heterogeneity in the literature regarding the ideal timing of drain removal, and therefore applied a narrower, more rigorous threshold in their population (≤15 mL/day for 3 consecutive days) that supports their findings. Regarding complications, the authors suggested that the increased incidence of fever may be related to the adverse effects of immunomodulatory agents, while the absence of secondary complications such as seroma or infection in the higher-concentration groups may reflect the same immunomodulatory effect, consistent with other studies suggesting that these agents promote lymphatic vessel closure and tissue healing through local immune activation, mediated by macrophages. Low rates of seroma and flap necrosis may also be attributable to surgical technique, given the submuscular anatomic plane and lateral incision approach used, as well described by Zhao et al. So, making comparisons between other techniques is an important next step in further research. Future trials should evaluate the superiority of PAP compared with already-established interventions for dead-space management and drainage reduction (9). Regarding the cosmetic outcomes, the authors emphasize the contribution of PAP to favorable results, attributing this to the immunomodulatory effect of macrophage proliferation, which they propose creates a favorable environment for reducing infection risk. However, the capsular contracture model the authors cite is merely theorical and mathematical, without clinical or experimental evidence, and none of its intermediate assumptions were actually measured (10). One of the major complications following immediate implant-based breast reconstruction is capsular contracture (11). We encourage the authors to consider a minimum follow-up period of 1 year to allow for an adequate assessment of capsular contracture development. Despite the favorable results reported, this article does not mention the use of adjuvant therapy, particularly radiotherapy. It could be worth exploring how will the presence of activated myofibroblasts react if radiation is needed. Also, how would this approach interface with acellular dermal matrix (ADM) incorporation (12)? These represent potential avenues for future research. Continued evaluation of this approach is warranted, despite promising outcomes, they are not yet robust enough to be extrapolated to a broader patient population without a deeper understanding of its safety. Regarding the study’s limitations, while it is one of the few current studies evaluating PAP as an adjunctive procedure, the sample size remains small and will require additional studies to establish its efficacy. Significant challenges remain in extrapolating this approach to other populations outside the Chinese population, in further elucidating the underlying mechanism behind these results, and in continuing to address patient safety. Although the results are favorable, the authors acknowledge these clear limitations, regarding that stills missing important information to be gathered; long-term consequences remain unknown, as the follow-up period is too short to determine these findings with certainty. This reinforces a broader principle: any innovation in breast reconstruction technique should not increase morbidity, and its adoption must be supported within the framework of evidence-based medicine by a clear balance between associated complications and a genuine improvement in patients’ quality of life (13), what Zhao et al. have taken an important step into that direction. Taking this into account, PAP represents a promising, but not yet definitive strategy. As far as we know, this is a relatively new and novel approach. Its initial results in this population are encouraging, but do not yet meet the standard of evidence required for widespread adoption in clinical practice. In agreement with the authors, multicenter studies with larger sample sizes and longer follow-up are needed to confirm both its safety and its true impact on clinically relevant outcomes. Until then, PAP should be considered an area of active investigation, rather than a standard of postoperative drainage management in NSM-IPR. This type of study should not remain an isolated, single-center finding. Regardless of whether PAP ultimately proves to be a viable strategy for reducing drain duration, it should serve as encouragement to continue developing strategies that are safe and effective for patients. Supplementary The article’s supplementary files as